Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Pharmaceutical K.K.
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center